• 1
    Bangma CH, Kranse R, Blijenberg BG, Schroder FH. The value of screening tests in the detection of prostate cancer. Part I. Results of a retrospective evaluation of 1726 men. Urology 1995; 46: 7738
  • 2
    Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 8438
  • 3
    Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 128390
  • 4
    Horninger W, Berger AP, Rogatsch H et al. Characteristics of prostate cancers detected at low PSA levels. Prostate 2004; 58: 2327
  • 5
    Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 15427
  • 6
    Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996; 47: 51824
  • 7
    Haese A, Dworschack RT, Partin AW. Percent free prostate specific antigen in the total prostate specific antigen 2–4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4–10 ng./ml. range. J Urol 2002; 168: 5048
  • 8
    Lilja H, Stenman UH. Successful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA. Cancer Treat Res 1996; 88: 93101
  • 9
    Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6–4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 14525
  • 10
    Horninger W, Reissigl A, Rogatsch H et al. Prostate cancer screening in Tyrol, Austria: experience and results. Eur Urol 1999; 35: 52338
  • 11
    Oesterling JE, Kumamoto Y, Tsukamoto T et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 1995; 75: 34753
  • 12
    Pelzer A, Bektic J, Berger AP et al. Prostate cancer detection in men with prostate specific antigen 4–10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 2005; 173: 19269
  • 13
    Sokoll LJ, Mangold LA, Partin AW et al. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. Urology 2002; 60 (Suppl. 1): 1823
  • 14
    Luderer AA, Chen YT, Soriano TF et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995; 46: 18794
  • 15
    Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 8604
  • 16
    Catalona WJ, Smith DS, Wolfert RL et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 121420
  • 17
    Carlson GD, Calvanese CB, Childs SJ. The appropriate lower limit for the percent free prostate-specific antigen reflex range. Urology 1998; 52: 4504
  • 18
    Presti JC Jr, O'Dowd GJ, Miller MC, Mattu R, Veltri RW. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 2003; 169: 1259
  • 19
    Gore JL, Shariat SF, Miles BJ et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 2001; 165: 15549
  • 20
    Singh H, Canto EI, Shariat SF et al. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 2004; 171: 108992
  • 21
    Chen ME, Troncoso P, Johnston DA, Tang K, Babaian RJ. Optimization of prostate biopsy strategy using computer based analysis. J Urol 1997; 158: 216875
  • 22
    Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997; 50: 5626
  • 23
    Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 223946